Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 129

1.

Predictive factors of herpes zoster HIV-infected patients: another adverse effect of crack cocaine.

Nacher M, Basurko C, Adenis A, Gaubert-Marechal E, Mosnier E, Edouard S, Vantilcke V, Sivapregassam S, Tressières B, Cabié A, Couppié P.

PLoS One. 2013 Nov 11;8(11):e80187. doi: 10.1371/journal.pone.0080187. eCollection 2013.

2.

Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users.

Baum MK, Rafie C, Lai S, Sales S, Page B, Campa A.

J Acquir Immune Defic Syndr. 2009 Jan 1;50(1):93-9. doi: 10.1097/QAI.0b013e3181900129.

PMID:
19295339
3.

Crack cocaine use increases the incidence of AIDS-defining events in French Guiana.

Nacher M, Adenis A, Hanf M, Adriouch L, Vantilcke V, El Guedj M, Vaz T, Dufour J, Couppié P.

AIDS. 2009 Oct 23;23(16):2223-6. doi: 10.1097/QAD.0b013e32833147c2.

PMID:
19752716
4.

Cocaine reduces thymic endocrine function: another mechanism for accelerated HIV disease progression.

Rafie C, Campa A, Smith S, Huffman F, Newman F, Baum MK.

AIDS Res Hum Retroviruses. 2011 Aug;27(8):815-22. doi: 10.1089/AID.2010.0086. Epub 2011 Jan 15.

5.

Primary varicella and herpes zoster among HIV-infected children from 1989 to 2006.

Wood SM, Shah SS, Steenhoff AP, Rutstein RM.

Pediatrics. 2008 Jan;121(1):e150-6. Epub 2007 Dec 17.

PMID:
18086820
6.

Incidence and predictors of herpes zoster among antiretroviral therapy-naïve patients initiating HIV treatment in Johannesburg, South Africa.

Shearer K, Maskew M, Ajayi T, Berhanu R, Majuba P, Sanne I, Fox MP.

Int J Infect Dis. 2014 Jun;23:56-62. doi: 10.1016/j.ijid.2013.10.016. Epub 2014 Mar 25.

7.

Herpes zoster in HIV-1-infected patients in the era of highly active antiretroviral therapy: a prospective observational study.

Hung CC, Hsiao CF, Wang JL, Chen MY, Hsieh SM, Sheng WH, Chang SC.

Int J STD AIDS. 2005 Oct;16(10):673-6.

PMID:
16212714
9.

Incidence and risk factors of herpes zoster among hiv-positive patients in the german competence network for HIV/AIDS (KompNet): a cohort study analysis.

Jansen K, Haastert B, Michalik C, Guignard A, Esser S, Dupke S, Plettenberg A, Skaletz-Rorowski A, Brockmeyer NH.

BMC Infect Dis. 2013 Aug 10;13:372. doi: 10.1186/1471-2334-13-372.

10.

Herpes zoster, immunological deterioration and disease progression in HIV-1 infection.

Veenstra J, Krol A, van Praag RM, Frissen PH, Schellekens PT, Lange JM, Coutinho RA, van der Meer JT.

AIDS. 1995 Oct;9(10):1153-8.

PMID:
8519451
11.

Predictors of CD4:CD8 ratio normalization and its effect on health outcomes in the era of combination antiretroviral therapy.

Leung V, Gillis J, Raboud J, Cooper C, Hogg RS, Loutfy MR, Machouf N, Montaner JS, Rourke SB, Tsoukas C, Klein MB; CANOC Collaboration.

PLoS One. 2013 Oct 30;8(10):e77665. doi: 10.1371/journal.pone.0077665. eCollection 2013.

12.

Low blood CD8+ T-lymphocytes and high circulating monocytes are predictors of HIV-1-associated progressive encephalopathy in children.

Sánchez-Ramón S, Bellón JM, Resino S, Cantó-Nogués C, Gurbindo D, Ramos JT, Muñoz-Fernández MA.

Pediatrics. 2003 Feb;111(2):E168-75.

PMID:
12563091
13.

The incidence of, risk factors for, and sequelae of herpes zoster among HIV patients in the highly active antiretroviral therapy era.

Gebo KA, Kalyani R, Moore RD, Polydefkis MJ.

J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):169-74.

PMID:
16186734
14.

Complications of varicella zoster virus reactivation in HIV-infected homosexual men.

Veenstra J, van Praag RM, Krol A, Wertheim van Dillen PM, Weigel HM, Schellekens PT, Lange JM, Coutinho RA, van der Meer JT.

AIDS. 1996 Apr;10(4):393-9.

PMID:
8728043
15.

Cocaine/crack use is not associated with fibrosis progression measured by AST-to-Platelet Ratio Index in HIV-HCV co-infected patients: a cohort study.

Martel-Laferrière V, Nitulescu R, Cox J, Cooper C, Tyndall M, Rouleau D, Walmsley S, Wong L, Klein MB; Canadian Co-infection Cohort Study Investigators.

BMC Infect Dis. 2017 Jan 17;17(1):80. doi: 10.1186/s12879-017-2196-0.

16.

Predictive factors for immunological and virological endpoints in Thai patients receiving combination antiretroviral treatment.

Srasuebkul P, Ungsedhapand C, Ruxrungtham K, Boyd MA, Phanuphak P, Cooper DA, Law MG.

HIV Med. 2007 Jan;8(1):46-54.

17.

Short-term and long-term effects of highly active antiretroviral therapy on the incidence of herpes zoster in HIV-infected children.

Levin MJ, Anderson JP, Seage GR 3rd, Williams PL; PACTG/IMPAACT 219C Team.

J Acquir Immune Defic Syndr. 2009 Feb 1;50(2):182-91. doi: 10.1097/QAI.0b013e31819550a4.

18.

Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIV-infected patients on long-term suppressive antiretroviral therapy.

Torti C, Prosperi M, Motta D, Digiambenedetto S, Maggiolo F, Paraninfo G, Ripamonti D, Cologni G, Fabbiani M, Caputo SL, Sighinolfi L, Ladisa N, El-Hamad I, Quiros-Roldan E, Frank I.

Clin Microbiol Infect. 2012 May;18(5):449-58. doi: 10.1111/j.1469-0691.2011.03650.x. Epub 2011 Sep 15.

19.

Varicella zoster as a manifestation of immune restoration disease in HIV-infected children.

Tangsinmankong N, Kamchaisatian W, Lujan-Zilbermann J, Brown CL, Sleasman JW, Emmanuel PJ.

J Allergy Clin Immunol. 2004 Apr;113(4):742-6.

PMID:
15100682
20.

Herpes zoster in women with and at risk for HIV: data from the Women's Interagency HIV Study.

Glesby MJ, Hoover DR, Tan T, Shi Q, Gao W, French AL, Maurer T, Young M, Dehovitz J, Ru J, Anastos K.

J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1604-9.

PMID:
15577417

Supplemental Content

Support Center